These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10752674)

  • 1. Involvement of CYP3A4 in the metabolism of bromperidol in vitro.
    Sato S; Someya T; Shioiri O; Koitabashi T; Inoue Y
    Pharmacol Toxicol; 2000 Mar; 86(3):145-8. PubMed ID: 10752674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes.
    Tateishi T; Watanabe M; Kumai T; Tanaka M; Moriya H; Yamaguchi S; Satoh T; Kobayashi S
    Life Sci; 2000 Nov; 67(24):2913-20. PubMed ID: 11133003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol.
    Fang J; Baker GB; Silverstone PH; Coutts RT
    Cell Mol Neurobiol; 1997 Apr; 17(2):227-33. PubMed ID: 9140699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol.
    Pan L; Belpaire FM
    Eur J Clin Pharmacol; 1999 Oct; 55(8):599-604. PubMed ID: 10541779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
    Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
    Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol.
    Pan LP; De Vriendt C; Belpaire FM
    Pharmacogenetics; 1998 Oct; 8(5):383-9. PubMed ID: 9825830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6.
    Damkier P; Brøsen K
    Clin Pharmacol Ther; 2000 Aug; 68(2):199-209. PubMed ID: 10976551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
    Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
    Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereoselective differences in the cytochrome P450-dependent dealkylation and demethylenation of N-methyl-benzodioxolyl-butanamine (MBDB, Eden) enantiomers.
    Meyer MR; Peters FT; Maurer HH
    Biochem Pharmacol; 2009 Jun; 77(11):1725-34. PubMed ID: 19428327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b(5) with recombinant P450 enzymes.
    Emoto C; Iwasaki K
    Xenobiotica; 2007 Sep; 37(9):986-99. PubMed ID: 17896325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.
    Uttamsingh V; Lu C; Miwa G; Gan LS
    Drug Metab Dispos; 2005 Nov; 33(11):1723-8. PubMed ID: 16103134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
    Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW
    Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry.
    Brøsen K
    Ther Drug Monit; 1996 Aug; 18(4):393-6. PubMed ID: 8857557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation.
    Kudo S; Odomi M
    Eur J Clin Pharmacol; 1998 May; 54(3):253-9. PubMed ID: 9681669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
    Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
    Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences.
    Johnson JA; Herring VL; Wolfe MS; Relling MV
    J Pharmacol Exp Ther; 2000 Sep; 294(3):1099-105. PubMed ID: 10945865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dehydrogenation of indoline by cytochrome P450 enzymes: a novel "aromatase" process.
    Sun H; Ehlhardt WJ; Kulanthaivel P; Lanza DL; Reilly CA; Yost GS
    J Pharmacol Exp Ther; 2007 Aug; 322(2):843-51. PubMed ID: 17502430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes.
    Olesen OV; Linnet K
    Drug Metab Dispos; 1997 Jun; 25(6):740-4. PubMed ID: 9193876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
    Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
    J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.
    Murayama N; Imai N; Nakane T; Shimizu M; Yamazaki H
    Biochem Pharmacol; 2007 Jun; 73(12):2020-6. PubMed ID: 17433262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.